Displaying drugs 776 - 800 of 831 in total
Rufloxacin
Rufloxacin is a quinolone antibiotic.
Experimental
Matched Categories: … Topoisomerase II Inhibitors …
VL-2397
Investigational
Mavorixafor
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Investigational
Matched Description: … HIV), Waldenstrom’s macroglobulinemia (WM), B-cell non-Hodgkin lymphoma, and solid tumours, including melanoma …
Etorphine
A narcotic analgesic morphinan used as a sedative in veterinary practice. In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes. Etorphine is only available to the patients under an official...
Illicit
Vet approved
Matched Description: … Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II …
R673
R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but...
Investigational
Matched Description: … The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear …
ChulaCov19 mRNA vaccine
The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678]. Pre-clinical studies in mice and monkeys showed evidence that the vaccine facilitates an impressive generation of neutralizing antibodies . The next phase of this study is for...
Investigational
Matched Description: … The next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January …
Tefidsogene civaparvovec
Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing. It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes. Developed by Sangamo...
Experimental
Matched Description: … Sangamo Therapeutics, tefidsogene civaparvovec is being investigated in mucopolysaccharidosis type II …
Temafloxacin
Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Withdrawn
Matched Categories: … Topoisomerase II Inhibitors …
Prulifloxacin
Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.
Investigational
Matched Categories: … Topoisomerase II Inhibitors …
Leronlimab
Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]
Investigational
Garenoxacin
Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Investigational
Matched Categories: … Topoisomerase II Inhibitors …
TAS-106
TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours .
Investigational
NAV 1800
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
IT-139
Investigational
FINLAY-FR-1
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute . It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and...
Investigational
Matched Description: … It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled …
AMG-222
Investigational
Garetosmab
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
LX201
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Bifeprunox
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Investigational
Dapoxetine
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation...
Investigational
Matched Description: … In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant …
Ramoplanin
Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Investigational
TST10088
TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. These molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis. TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by...
Investigational
Matched Description: … TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating …
Fluprednidene
Fluprednidene is a corticosteroid.
Experimental
Matched Categories: … Corticosteroids, Moderately Potent (Group II) …
Clinafloxacin
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Categories: … Topoisomerase II Inhibitors …
N-(2-Aminoethyl)-1-aziridineethanamine
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).
Experimental
Displaying drugs 776 - 800 of 831 in total